North America expected to provide high business for the atopicdermatitis market  2019-2024

North America expected to provide high business for the atopicdermatitis market 2019-2024

May 13, 2019 Off By BusinessWire

Dermatitis Market – Growth, Trends, and Forecast (2019 – 2024)”

report has been added to’s

Food allergy has been essentially highly debatable for decades in atopic
dermatitis, with some common food, including milk, egg, and soy. There
is a lot of literature which provides evidence that common food
exacerbate atopic dermatitis.

The malfunction in the immune system of the human body due to asthma is
also among the major causes for atopic dermatitis. In addition, skin
irritants also occur because of certain soaps, detergents, perfumes etc.
Thus, the allergic reactions particularly due to food is one major
factor increasing the burden of atopic dermatitis and driving this

Other factors driving this market is the rich pipeline portfolio with
products in advanced stages of clinical development, increasing
government funds to support research for this disease, and rising
campaigns to raise eczema awareness.

Corticosteroids Dominated the Overall Market, by Drug Class

Corticosteroids are referred to as cortisone-like medicines that are
used as pain relief medication for inflammation in the body. These drugs
are known to have effects, such as reduced itching, swelling, allergic
reactions, and redness. In addition, these drugs are use as the first
line treatment for different diseases, such as skin problems, severe
allergies, arthritis, and asthma. Around 30 corticosteriod compounds
have been licensed for atopic dermatitis treatment of which
Hydrocortisone is considered to be the first.

The rising innovations have led to the advent of counterfeit medicines
and alternative drugs such as immuno-modulators pimecrolimus, and
tacrolimus. However, these alternatives have pitfalls, such as selective
effectiveness and high cost. Hence, topical corticosteroids play a vital
role in the atopic dermatitis treatment.

North America Captured the Largest Market Share, and is
Expected to Retain Its Dominance

North America is expected to provide high business for the atopic
dermatitis market, over the forecast period, 2019-2024. The factors,
such as high treatment awareness among the patient population across the
United States and Canada, healthcare infrastructure, early adoption of
novel medications, better reimbursement policies, and increasing
business partnerships of pharmaceutical companies with contract research
organizations in the emerging markets help the lucrative nature of this
market in North America.

Though both countries deal with heavy healthcare expenditure, there are
an increasing number of campaigns organized each year by certain
foundations, such as the PAN Foundation, National Eczema Associations,
and pharmaceutical companies along with grants.

Competitive Landscape

The presence of major market players, such as Pfizer, F Hoffmann-La
Roche, Allergan, Novartis, and Bayer AG, is increasing the overall
competitive rivalry of the market. Large organizations rely heavily on
advertising expenses and branding strategies. They are also
collaborating with successful personalities, initiatives, or programs at
the national levels, which promote their product, and are, thus,
recognized earlier than other brands in the market.

Key Topics Covered





4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Burden of Allergic Reactions with Major Role of Food

4.2.2 Growing Government Expenditure Regarding Atopic Dermatitis

4.2.3 Increasing Campaigns to Raise Atopic Dermatitis Awareness

4.3 Market Restraints

4.3.1 Costs Variations of Treatments Limits Patient Access

4.3.2 Serious Adverse Effects Related to Certain Therapeutic Drugs

4.4 Porter’s Five Forces Analysis


5.1 By Drug Class

5.1.1 Corticosteroids

5.1.2 Emollients/Moisturizers

5.1.3 IL-4 & PDE4 Inhibitors

5.1.4 Calcineurin inhibitors

5.1.5 Antibiotics

5.1.6 Other Drug Classes

5.2 By Administration Type

5.2.1 Topical

5.2.2 Oral

5.2.3 Injectable

5.3 Prescription Type

5.3.1 Over-the-counter (OTC)

5.3.2 Prescription

5.4 Geography

5.4.1 North America

5.4.2 Europe

5.4.3 Asia-Pacific

5.4.4 Middle East & Africa

5.4.5 South America


6.1 Company Profiles

6.1.1 Abbvie Inc.

6.1.2 Allergan PLC

6.1.3 Bausch Health Companies Inc.

6.1.4 GlaxoSmithKline PLC

6.1.5 Encore Dermatology Inc.

6.1.6 Nestle

6.1.7 LEO Pharma A/S

6.1.8 Novartis International AG

6.1.9 Pfizer Inc.

6.1.10 Regeneron Pharmaceuticals Inc.


For more information about this report visit

Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Dermatology